Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Stage IV Non-small Cell Lung Cancer: early-phase trial registry
4 of 24 indexed Stage IV Non-small Cell Lung Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #686 of 28,707 conditions by registered trial count.
24 US clinical trials · 4 currently recruiting · #686 of 28,707 conditions by registered trial count
Stage IV Non-small Cell Lung Cancer: 24 US clinical trials tracked, 4 recruiting.
Stage IV Non-small Cell Lung Cancer is the subject of 24 registered US clinical trials on ClinicalTrials.gov, 4 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 19 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 9 of these trials.
Enrollment posture brief
Registry condition stage-iv-non-small-cell-lung-cancer
OPEN 4 | RECR 17% | LATE 0 | EARLY 19 | RANK #686 | SPON 9
Volume-matched condition peers
Nearest open-share peer: Acute Renal Failure (17% recruiting · 6 trials)
Stage IV Non-small Cell Lung Cancer lists 4 open slots (17% of 24 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Stage IV Non-small Cell Lung Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Stage IV Non-small Cell Lung Cancer is recruiting below its size-band peers.
4 of 24 indexed trials (16.7%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Stage IV Non-small Cell Lung Cancer research.
National Cancer Institute (NCI) accounts for 9 of 24 trials (37.5%). 15 distinct sponsors appear on at least one study for this condition label.
-
Most Stage IV Non-small Cell Lung Cancer trials plan to enrol fewer than 100 people.
Median target enrolment is 53 among the 24 trials that report a genuine target (sentinel values excluded). 18 of those (75%) plan for fewer than 100 participants.
-
Stage IV Non-small Cell Lung Cancer research is mostly interventional.
23 interventional and 1 observational studies make up this index (95.8% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
24 total, page 1 of 1
Beating Lung Cancer in Ohio Protocol in Improving Survival in Patients With Stage IV Non-Small Cell Lung Cancer
Ohio State University Comprehensive Cancer Center
NCT03199651
Comprehensive Genomic Analysis in Tissue Samples From Patients With Recurrent or Stage IV Non-small Cell Lung Cancer
Barbara Ann Karmanos Cancer Institute
NCT02178163
Patient-centered, Optimal Integration of Survivorship and Palliative Care
Massachusetts General Hospital
NCT04900935
A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer
Iovance Biotherapeutics
NCT05361174
Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments
OncoHost
NCT04056247
Maintenance Chemotherapy With or Without Local Consolidative Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer
NRG Oncology
NCT03137771
S1403, Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer
SWOG Cancer Research Network
NCT02438722
Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLC
H. Lee Moffitt Cancer Center and Research Institute
NCT03611738
Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC
H. Lee Moffitt Cancer Center and Research Institute
NCT05681780
Ruxolitinib for Cancer Cachexia
Tu Dan
NCT04906746
Erlotinib in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
NCT00085280
Azacitidine and Entinostat in Treating Patients With Recurrent Advanced Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
NCT00387465
Erlotinib and Celecoxib in Treating Patients With Stage IIIB or Stage IV Recurrent Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
NCT00062101
S0341: Erlotinib in Treating Patients With Advanced Primary Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
NCT00087412
Effects of Carboplatin and Gemcitabine on Stage IIIB Pleural Effusion and Stage IV Lung Cancer
Susanne Arnold
NCT00247416
CCI-779 in Treating Patients With Stage IIIB (With Pleural Effusion) or Stage IV Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
NCT00079235
Tipifarnib, Gemcitabine, and Cisplatin in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
NCT00055757
Effect of Pembrolizumab With or Without Carboplatin and Paclitaxel on Immune Response in Patients With Recurrent or Stage IIIB-IV Non-small Cell Lung Cancer
Wake Forest University Health Sciences
NCT02581943
Bortezomib in Treating Patients With Stage IIIB or Stage IV Lung Cancer
National Cancer Institute (NCI)
NCT00118144
Bortezomib Plus Gemcitabine and Carboplatin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
NCT00052338
Erlotinib Hydrochloride With or Without Cixutumumab in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
NCT00778167
Pembrolizumab Alone or Sequentially Following Single Fraction Non-ablative Radiation to One of the Target Lesions, in Previously Treated Patients With Stage IV NSCLC
Case Comprehensive Cancer Center
NCT02658097
Stereotactic Body Radiation Therapy After Surgery in Treating Patients With Stage III-IV Non-small Cell Lung Cancer
Roswell Park Cancer Institute
NCT01781741
Exemestane, Pemetrexed Disodium, and Carboplatin in Treating Post-Menopausal Women With Stage IV Non-Small Cell Lung Cancer
Jonsson Comprehensive Cancer Center
NCT01664754
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 9 |
| Phase 2 | 10 |
Top Sponsors
Named interventions
Most-linked intervention names on Stage IV Non-small Cell Lung Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Stage IV Non-small Cell Lung Cancer trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Stage IV Non-small Cell Lung Cancer page
24 registered trials, 4 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 4 Stage IV Non-small Cell Lung Cancer trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Cancer Institute (NCI) sponsors the most Stage IV Non-small Cell Lung Cancer trials on record, review their full trial history before evaluating a specific study. See National Cancer Institute (NCI)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Stage IV Non-small Cell Lung Cancer condition card totals 24 registered trials; most-linked intervention laboratory biomarker analysis; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.